2020
DOI: 10.3389/fnhum.2020.578695
|View full text |Cite
|
Sign up to set email alerts
|

Researcher Perspectives on Ethical Considerations in Adaptive Deep Brain Stimulation Trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
23
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 31 publications
(23 citation statements)
references
References 41 publications
(23 reference statements)
0
23
0
Order By: Relevance
“…We developed the interview guide based on a review of key issues and concerns identified in the bioethics and neuroethics literature on data sharing, during participant observation in a lab conducting aDBS research, and in discussions with other experts. While the interview guide included additional questions related to other important neuroethics issues (including what researchers view as the most pressing ethical issues in aDBS research, what issues they have personally encountered in their research, and questions about specific features of aDBS), we report researchers' views on those topics elsewhere (Muñoz et al, 2020) and report here specifically on results about researchers' attitudes and perspectives towards data sharing. We have used identification numbers in this piece that are different than those in Muñoz et al (2020) to help ensure de-identification of researcher-participants.…”
Section: Methodsmentioning
confidence: 99%
“…We developed the interview guide based on a review of key issues and concerns identified in the bioethics and neuroethics literature on data sharing, during participant observation in a lab conducting aDBS research, and in discussions with other experts. While the interview guide included additional questions related to other important neuroethics issues (including what researchers view as the most pressing ethical issues in aDBS research, what issues they have personally encountered in their research, and questions about specific features of aDBS), we report researchers' views on those topics elsewhere (Muñoz et al, 2020) and report here specifically on results about researchers' attitudes and perspectives towards data sharing. We have used identification numbers in this piece that are different than those in Muñoz et al (2020) to help ensure de-identification of researcher-participants.…”
Section: Methodsmentioning
confidence: 99%
“…are likewise being explored for use as enhancements ( Kreitmair, 2019 ; Wexler and Reiner, 2019 ), we focus here specifically on aDBS, which differs from most other neurotechnologies by virtue of being an invasive, surgically implanted technology with an established capacity to both read and write to the brain, meaning the device can monitor as well as independently and automatically stimulate brain activity. This closed-loop technology, once further developed, would bypass the need for active monitoring or intervention by a human agent and raise ethical questions related to data privacy and security, patient informed consent and understanding ( Muñoz et al, 2020 ), and the need to preserve personal autonomy ( Zuk and Lázaro-Muñoz, 2019a ), agency, and identity ( Lázaro-Muñoz et al, 2017 ). When used in the context of experimental clinical settings, aDBS devices raise additional concerns about post-trial continued access ( Muñoz et al, 2020 ) to and/or removal of devices ( Sierra-Mercado et al, 2019 ) for participants in research trials after the study period is over.…”
Section: Introductionmentioning
confidence: 99%
“…This closed-loop technology, once further developed, would bypass the need for active monitoring or intervention by a human agent and raise ethical questions related to data privacy and security, patient informed consent and understanding ( Muñoz et al, 2020 ), and the need to preserve personal autonomy ( Zuk and Lázaro-Muñoz, 2019a ), agency, and identity ( Lázaro-Muñoz et al, 2017 ). When used in the context of experimental clinical settings, aDBS devices raise additional concerns about post-trial continued access ( Muñoz et al, 2020 ) to and/or removal of devices ( Sierra-Mercado et al, 2019 ) for participants in research trials after the study period is over. The intentional expansion of aDBS technology into the commercial sphere for non-clinical and elective ( Neuralink Inc, 2022 ) uses evokes further concerns, both practical (related to function and efficacy) and ethical (related to moral rightness or wrongness), revolving around safety (that it could potentially harm consumers) ( Jarchum, 2019 ), data security/privacy (brain activity could be accessed by unwanted third parties, “hacked” or otherwise exploited or exchanged as “currency” via licensing agreements) ( Dresler et al, 2018 ), and free will (that neuroenhancement may threaten our understanding of human agency, responsibility and liability) ( Nahmias et al, 2014 ; Klein et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%
“…Although caregiver relationships are often characterized by support, in some instances they may introduce tension and disagreement in a patients' experience and interpretation of DBS effects (Klein et al 2016). As emotional experiences can be deeply situated within social contexts, it will be essential to understand the role of close others when aiming to support patients' development of self-trust, as well as the impact of DBS on agency more broadly (Muñoz et al 2020;Brown 2020;Klein et al 2016;Goering et al 2017;Mackenzie 2014).…”
mentioning
confidence: 99%
“…Advances in technology and neuroscientific knowledge hope to bring a clearer distinction between instances where stimulation should be autonomously adapted independently of patient input versus stimulation in which they should be kept "in the loop" in order to assess and potentially alter its effects (Muñoz et al 2020;Klein et al 2016;Goering 2015). Maybe Cora would prefer to be able to "self-modulate" her DBS in order to best attune the effects of stimulation to the demands of her everyday life, in this case preferring to have the capacity to engage in a particular kind of emotional expression at a funeral.…”
mentioning
confidence: 99%